What's in Jaeb Center for Health Research's pipeline?

Jaeb Center for Health Research has 9 drugs in our index: 1 marketed, 0 filed, 8 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Jaeb Center for Health Research's portfolio?

Top competitors by shared drug class: Alvotech Swiss AG, Hawaii Pacific Health, Hospital Regional de São José - Dr. Homero de Miranda Gomes, Marashi Eye Clinic, Moorfields Eye Hospital NHS Foundation Trust.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jaeb-center-for-health-research.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Jaeb Center for Health Research — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jaeb Center for Health Research pipeline: 1 marketed, 0 filed, 8 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 8 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
intravitreous aflibercept	intravitreous aflibercept	marketed
Deferred aflibercept	Deferred aflibercept	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF (vascular endothelial growth factor), PlGF (placental growth factor)	Ophthalmology / Oncology
Prompt aflibercept	Prompt aflibercept	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF (vascular endothelial growth factor), PlGF (placental growth factor)	Oncology, Ophthalmology
Bevacizumab + Deferred Aflibercept Group	Bevacizumab + Deferred Aflibercept Group	phase 3	Anti-angiogenic agents; VEGF inhibitors	VEGF-A (bevacizumab); VEGF-A, VEGF-B, PlGF (aflibercept)	Oncology
Ranibizumab + deferred laser	Ranibizumab + deferred laser	phase 3	anti-VEGF agent	VEGF-A	Ophthalmology
Ranibizumab + laser	Ranibizumab + laser	phase 3	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A	Ophthalmology
Sham injection + laser	Sham injection + laser	phase 3			Dermatology
Placebo Eyedrops	Placebo Eyedrops	phase 3			Ophthalmology
Triamcinolone Acetonide + laser	Triamcinolone Acetonide + laser	phase 3	Corticosteroid + laser therapy combination	Glucocorticoid receptor	Ophthalmology

Therapeutic area mix

Ophthalmology · 4
Dermatology · 1
Oncology · 1
Oncology, Ophthalmology · 1
Ophthalmology / Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alvotech Swiss AG · 1 shared drug class
Hawaii Pacific Health · 1 shared drug class
Hospital Regional de São José - Dr. Homero de Miranda Gomes · 1 shared drug class
Marashi Eye Clinic · 1 shared drug class
Moorfields Eye Hospital NHS Foundation Trust · 1 shared drug class
Novartis · 1 shared drug class
ONL Therapeutics · 1 shared drug class
Retinal Consultants of Arizona · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jaeb Center for Health Research:

Cite this brief

Drug Landscape (2026). Jaeb Center for Health Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jaeb-center-for-health-research. Accessed 2026-05-17.